{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T11:53:51Z","timestamp":1772193231699,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"vor","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioMed Eng OnLine"],"DOI":"10.1186\/s12938-026-01530-9","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:06:42Z","timestamp":1769846802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors and predicted model for clinical relapse after antiviral therapy cessation in chronic hepatitis B patients: a retrospective real-world data analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiyan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"key":"1530_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jhep.2024.08.010","volume":"82","author":"M Buti","year":"2025","unstructured":"Buti M, Heo J, Tanaka Y, Andreone P, Atsukawa M, Cabezas J, et al. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B. J Hepatol. 2025;82:222\u201334.","journal-title":"J Hepatol"},{"key":"1530_CR2","doi-asserted-by":"publisher","first-page":"486","DOI":"10.14309\/ajg.0000000000002468","volume":"119","author":"HLY Chan","year":"2024","unstructured":"Chan HLY, Buti M, Lim YS, Agarwal K, Marcellin P, Brunetto M, et al. Long-term treatment with tenofovir alafenamide for chronic hepatitis B results in high rates of viral suppression and favorable renal and bone safety. Am J Gastroenterol. 2024;119:486\u201396.","journal-title":"Am J Gastroenterol"},{"key":"1530_CR3","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/S2468-1253(24)00096-7","volume":"9","author":"HLA Janssen","year":"2024","unstructured":"Janssen HLA, Lim YS, Lampertico P, Heo J, Chen CY, Fournier C, et al. Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2024;9:718\u201333.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1530_CR4","doi-asserted-by":"publisher","first-page":"724","DOI":"10.3390\/v16050724","volume":"16","author":"DA Asandem","year":"2024","unstructured":"Asandem DA, Segbefia SP, Kusi KA, Bonney JHK. Hepatitis B virus infection: a mini review. Viruses. 2024;16:724.","journal-title":"Viruses"},{"key":"1530_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28436","volume":"95","author":"A Kar","year":"2023","unstructured":"Kar A, Samanta A, Mukherjee S, Barik S, Biswas A. The HBV web: an insight into molecular interactomes between the hepatitis B virus and its host en route to hepatocellular carcinoma. J Med Virol. 2023;95:e28436.","journal-title":"J Med Virol"},{"key":"1530_CR6","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S2468-1253(23)00148-6","volume":"8","author":"MF Yuen","year":"2023","unstructured":"Yuen MF, Asselah T, Jacobson IM, Brunetto MR, Janssen HLA, Takehara T, et al. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial. Lancet Gastroenterol Hepatol. 2023;8:790\u2013802.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1530_CR7","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","volume":"9","author":"MF Yuen","year":"2024","unstructured":"Yuen MF, Lim YS, Yoon KT, Lim TH, Heo J, Tangkijvanich P, et al. VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study. Lancet Gastroenterol Hepatol. 2024;9:1121\u201332.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1530_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jhep.2022.05.014","volume":"77","author":"S Yoo","year":"2022","unstructured":"Yoo S, Kim JY, Lim YS, Han S, Choi J. Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. J Hepatol. 2022;77:939\u201346.","journal-title":"J Hepatol"},{"key":"1530_CR9","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","volume":"162","author":"G Hirode","year":"2022","unstructured":"Hirode G, Choi HSJ, Chen CH, Su TH, Seto WK, Van Hees S, et al. Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B study). Gastroenterology. 2022;162:757-771.e4.","journal-title":"Gastroenterology"},{"key":"1530_CR10","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.14309\/ajg.0000000000002203","volume":"118","author":"G Hirode","year":"2023","unstructured":"Hirode G, Hansen BE, Chen CH, Su TH, Wong G, Seto WK, et al. Incidence of hepatic decompensation after nucleos(t)ide analog withdrawal: results from a large, international, multiethnic cohort of patients with chronic hepatitis B (RETRACT-B study). Am J Gastroenterol. 2023;118:1601\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1530_CR11","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1136\/gutjnl-2023-330691","volume":"72","author":"Z Liu","year":"2023","unstructured":"Liu Z, Lin C, Mao X, Guo C, Suo C, Zhu D, et al. Changing prevalence of chronic hepatitis B virus infection in China between 1973 and 2021: a systematic literature review and meta-analysis of 3740 studies and 231 million people. Gut. 2023;72:2354\u201363.","journal-title":"Gut"},{"key":"1530_CR12","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","volume":"391","author":"J Hou","year":"2024","unstructured":"Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B. N Engl J Med. 2024;391:2098\u2013109.","journal-title":"N Engl J Med"},{"key":"1530_CR13","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1016\/j.cgh.2022.07.005","volume":"21","author":"HSJ Choi","year":"2023","unstructured":"Choi HSJ, Hirode G, Chen CH, Su TH, Seto WK, Van Hees S, et al. Differential relapse patterns after discontinuation of entecavir vs. tenofovir disoproxil fumarate in chronic hepatitis B. Clin Gastroenterol Hepatol. 2023;21:1513-1522.e4.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1530_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.879835","volume":"13","author":"X Lin","year":"2022","unstructured":"Lin X, Song A, Lu J, Zheng S, Hu Z, Ma L, et al. Study on the retreatment, outcome, and potential predictors of recurrence in patients with recurrence of hepatitis B after functional cure. Front Immunol. 2022;13:879835.","journal-title":"Front Immunol"},{"key":"1530_CR15","first-page":"3711","volume":"11","author":"IC Lee","year":"2021","unstructured":"Lee IC, Lei HJ, Chau GY, Yeh YC, Wu CJ, Su CW, et al. Predictors of long-term recurrence and survival after resection of HBV-related hepatocellular carcinoma: the role of HBsAg. Am J Cancer Res. 2021;11:3711\u201325.","journal-title":"Am J Cancer Res"},{"key":"1530_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/hepr.13749","volume":"52","author":"M Luo","year":"2022","unstructured":"Luo M, Zhou B, Hou J, Jiang D. Biomarkers for predicting nucleos(t)ide analogs discontinuation and hepatitis B virus recurrence after drug withdrawal in chronic hepatitis B patients. Hepatol Res. 2022;52:337\u201351.","journal-title":"Hepatol Res"},{"key":"1530_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3350\/cmh.2023.0194","volume":"30","author":"YN Tsai","year":"2024","unstructured":"Tsai YN, Wu JL, Tseng CH, Chen TH, Wu YL, Chen CC, et al. Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation. Clin Mol Hepatol. 2024;30:98\u2013108.","journal-title":"Clin Mol Hepatol"},{"key":"1530_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00535-022-01855-x","volume":"57","author":"XH Wang","year":"2022","unstructured":"Wang XH, Hu ZL, Fu YZ, Hou JY, Li WX, Zhang YJ, et al. Tenofovir vs. entecavir on prognosis of hepatitis B virus-related hepatocellular carcinoma after curative resection. J Gastroenterol. 2022;57:185\u201398.","journal-title":"J Gastroenterol"},{"key":"1530_CR19","first-page":"314","volume":"11","author":"W Gan","year":"2023","unstructured":"Gan W, Gao N, Gu L, Mo Z, Pang X, Lei Z, et al. Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure. J Clin Transl Hepatol. 2023;11:314\u201322.","journal-title":"J Clin Transl Hepatol"},{"key":"1530_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1427043","volume":"11","author":"W Xu","year":"2024","unstructured":"Xu W, Luo Q, Zhang Y, Xie C, Peng L. A case report: cccDNA and pgRNA remain positive in liver tissue in a chronic hepatitis B patient with functional cure. Front Med. 2024;11:1427043.","journal-title":"Front Med"},{"key":"1530_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","volume":"166","author":"MJ Sonneveld","year":"2024","unstructured":"Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. HBV DNA and HBsAg levels at 24 weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy. Gastroenterology. 2024;166:168-177.e8.","journal-title":"Gastroenterology"},{"key":"1530_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100790","volume":"5","author":"MJ Sonneveld","year":"2023","unstructured":"Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, et al. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: a multicentre cohort study. JHEP Rep. 2023;5:100790.","journal-title":"JHEP Rep"},{"key":"1530_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/biom15010062","volume":"15","author":"A Boonstra","year":"2025","unstructured":"Boonstra A, Sari G. HBV cccDNA: the molecular reservoir of hepatitis B persistence and challenges to achieve viral eradication. Biomolecules. 2025;15:62.","journal-title":"Biomolecules"},{"key":"1530_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-86555-1","volume":"15","author":"L Han","year":"2025","unstructured":"Han L, Wang Z, Kang L, Cui X, Li Y, Yin H, et al. Predicting relapse after achieving a functional cure for chronic hepatitis B (CHB) using baseline HBsAg and end-of-treatment HBsAb levels. Sci Rep. 2025;15:13873.","journal-title":"Sci Rep"},{"key":"1530_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859430","volume":"9","author":"A Kaewdech","year":"2022","unstructured":"Kaewdech A, Assawasuwannakit S, Sripongpun P, Chamroonkul N, Tangkijvanich P, Piratvisuth T. Clinical utility of SCALE-B to predict hepatitis B virus relapse, hepatitis B surface antigen loss after antiviral cessation in Asian patients after 2-year follow-up. Front Med. 2022;9:859430.","journal-title":"Front Med"},{"key":"1530_CR26","first-page":"1425","volume":"11","author":"H You","year":"2023","unstructured":"You H, Wang F, Li T, Xu X, Sun Y, Nan Y, et al. Guidelines for the prevention and treatment of chronic hepatitis B (version 2022). J Clin Transl Hepatol. 2023;11:1425\u201342.","journal-title":"J Clin Transl Hepatol"},{"key":"1530_CR27","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1111\/jvh.13729","volume":"29","author":"M Papatheodoridi","year":"2022","unstructured":"Papatheodoridi M, Papachristou E, Moschidis Z, Hadziyannis E, Rigopoulou E, Zachou K, et al. Significance of serum HBV RNA in non-cirrhotic HBeAg-negative chronic hepatitis B patients who discontinue effective antiviral therapy. J Viral Hepat. 2022;29:948\u201357.","journal-title":"J Viral Hepat"}],"container-title":["BioMedical Engineering OnLine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12938-026-01530-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12938-026-01530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12938-026-01530-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:46:40Z","timestamp":1772189200000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12938-026-01530-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1186\/s12938-026-01530-9","relation":{},"ISSN":["1475-925X"],"issn-type":[{"value":"1475-925X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by The Ethics Committee of Southern Central Hospital of Yunnan Province (The First People\u2019s Hospital of Honghe State). Informed consent was obtained from participants for the participation in the study and all methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"38"}}